09:40 AM EST - Aeterna Zentaris Inc. : Announced that results from pre-clinical studies of Aeterna’s AIM Biologicals (Autoimmunity Modifying Biologicals) for the potential treatment of neuromyelitis optica spectrum disorder were accepted for presentation at the 13th International Congress on Autoimmunity to be held June 10-13, in Athens, Greece. Aeterna Zentaris Inc.
shares T.AEZS are trading up $0.005 at $0.45.
